The United States Food and Drugs Administration Approves a Generic Enoxaparin

Abstract

The Food and Drug Administration (FDA) approved on July 23, 2010, the abbreviated new drug application (ANDA) by Sandoz Inc for a generic enoxaparin (Lovenox) as the FDA is satisfied with the active ingredient ‘‘sameness’’ and the interchangeability of Lovenox with this generic version. Regulatory authorities that consider low-molecular-weight heparins (LMWHs) as drugs approve generic LMWHs via an ANDA pathway, whereas EMEA views them as biological medicines and will therefore regulate copies of LMWHs via a biosimilar pathway because only similar copies can be manufactured. Furthermore, European Medicines Agency (EMEA) requires appropriately powered clinical trails to establish comparable efficacy and safety profiles for biosimilar and their branded LMWHs counterparts. The safety issues that have led to withdrawal of some generic LMWHs from some Asian and South American countries mandate the need for a broad consensus defining the minimum attributes copies of LMWHs required for efficacy and safety.

Keywords

low molecular weight heparins thrombosis prophylaxis deep venous thrombosis heparins

References

FDA News Release, July 23, 2010. fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm220092.hm. Accessed July 23, 2010.

FDA response to Citizen Petition Docket No. FDA-2003-P-0273 .

Drugs. Establishing Active Ingredient Sameness for Generic Enoxaparin Sodium, a Low Molecular Weight Heparin. fda.gov/Drugs/DrugsSafety/Post-marketDrugSafetyInformationforPatients-andProviders/ucm220023 . Accessed July 28, 2010.

Drugs. Generic Enoxaparin Questions and Answers. fda.gov/Drugs/DrugSafety/PostmarketDugSfetyIformationforPtientsandProviders. Accessed July 26, 2010.

Drugs. Abbreviated New Drug applications (ANDA): Generics . fda.gov/Drug/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved . Accessed July 26, 2010.

Kalodiki E. , Leon w ; SASAT, and Task Force on Generic LMWHs. SASAT (South Asian Society on Atherosclerosis and Thrombosis) proposal for regulatory guidelines for generic low molecular weight heparins (LMWHs). Clin Appl Thromb Hemost. 2009;15(1):8-11.

North American Thrombosis Forum Official Policy Statement regarding the protection of patient safety and patient rights on the matter of follow-on biologics. natfonline.org/NATFbiologiesstatement.php . Accessed July 26, 2010.

North American Thrombosis Forum Thoughts on Approval Guidelines for Generic Heparins and Low Molecular Weight Heparins. Written Communications to the FDA. http://www.natfonline.org/FINAL%20natf%20Written%20communication%20to%20FDA.pdf. Accessed on June 15, 2010.

Kalodiki E. , Fareed J. , Tapson WF , et al. A consensus conference on complex biologics and low molecular weight heparin. Int Angiol. 2010;29:193-196.

10.

EMEA Guidelines on Clinical and Non-Clinical Development of Medicinal Products Containing Low-Molecular-Weight Heparins. London: European Medical Agency; 2009. EMEA/CHMP/BMWP/11826407enfin.pdf. Accessed July 29, 2010.

11.

Harenberg J. , Kakkar A. , Bergqvist D. , et al, on behalf of the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Recommendations on biosimilar low-molecular-weight heparins. J Thromb Haemost . 2009;7(7):1222-1225.

12.

Emea. Guidelines on Similar Biologic Medical Products Containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues. London: European Medicines Agency; 2006 (EMEA/CHMP/BMWP/42832/2005). http://www.emea.europa.eu/pdfs/human/biosimilar/4283205en.pdf . Accessed July 26, 2010.

13.

Pharmaceutical Research and Manufacturers of America. Pharmaceutical Industry Profile 2007. Washington, DC: PHRMA, 2007. http//.phrma.org/files/attachments/2008%20Profile.pdf . Accessed August 18, 2010.

14.

WHO 2009. Guidelines on evaluation of similar biotherapeutic products (SBPs). who.int/biologicals/areas/biological_therapeutic/BIOTHERAPETUTICS_FOR_WEB_22APRIL2010_WI . Accessed August 18, 2010.

15.

United States Government. 111th Congress of the United States of America. The Patient Protection and Affordable care Act. HR 3590. March 2010. http://democrats.senate.gov./reform/patientprotection-affordable-care-act-as-passed.pdf . Accessed June 11, 2010.